- Home
- AVTX
as 11-26-2025 3:21pm EST
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WAYNE |
| Market Cap: | 248.3M | IPO Year: | 2015 |
| Target Price: | $30.14 | AVG Volume (30 days): | 351.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.39 - $19.41 | Next Earning Date: | 11-06-2025 |
| Revenue: | $192,000 | Revenue Growth: | -76.58% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Avalo Therapeutics Inc. (AVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Goldman Jonathan | AVTX | Director | Nov 14 '25 | Sell | $14.32 | 11,367 | $162,936.78 | 0 |
Latest Avalo Therapeutics Inc. News
AVTX Breaking Stock News: Dive into AVTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
15 days ago
Leukocyte Adhesion Deficiency Market Analysis and Forecast, 2025-2035, Featuring Rocket Pharmaceuticals, Avalo Therapeutics, Orpha Labs, and AUG Therapeutics
GlobeNewswire
21 days ago
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
GlobeNewswire
24 days ago
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Insider Monkey
a month ago
Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX)
MT Newswires
3 months ago
TD Cowen Initiates Avalo Therapeutics at Buy
GlobeNewswire
5 months ago
Avalo Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
5 months ago
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
Compare AVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVTX Avalo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.